Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Maternal exposure timing unspecified? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Maternal exposure timing unspecified have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.0% of all adverse event reports for DOXORUBICIN.

13
Reports of Maternal exposure timing unspecified with DOXORUBICIN
0.0%
of all DOXORUBICIN reports
0
Deaths
2
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From DOXORUBICIN?

Of the 13 reports, 2 (15.4%) required hospitalization.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which DOXORUBICIN Alternatives Have Lower Maternal exposure timing unspecified Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified DOXORUBICIN Demographics